Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Study ID: NCT02090530
Start Date: 2013-11-04
End Date: 2025-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1000

Intervention / Treatment

Biospecimen collection

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Study ID: NCT04792073
Start Date: 2021-03-08
End Date: 2026-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

18

Intervention / Treatment

Avelumab

Comprehensive Ablative Radiation Therapy

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Study ID: NCT06586957
Start Date: 2024-09-19
End Date: 2029-05
Study Type

Interventional

Study Phase

Phase1

No. of Participants

90

Intervention / Treatment

We disobey 4

Sponsor

NiKang Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Study ID: NCT06770582
Start Date: 2025-06-03
End Date: 2032-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

160

Intervention / Treatment

Biospecimen Collection

Cisplatin

Computed Tomography

Fluorouracil

Gemcitabine

Magnetic Resonance Imaging

Mitomycin

Pembrolizumab

Administration questionnaire

Radiation Therapy

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Study ID: NCT07023731
Start Date: 2025-05-29
End Date: 2029-04-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

159

Intervention / Treatment

ARV-806

Sponsor

Arvinas Inc.

Source: clinicaltrials.gov

Share:
Add to list

Inpatient Capture: A Mixed Methods Study to Develop an Inpatient Lung Cancer Screening Program in a Safety Net Hospital.

Study ID: NCT06876831
Start Date: 2025-03-10
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

150

Intervention / Treatment

Shared decision making for LDCT (3 potential outcomes LDCT on discharge, scheduled date of LDCT, or Lung Cancer Screening referral)

Inpatient Tobacco Cessation Counseling (Handouts, NYC Quits number, Medication Recommendations to primary team, Smoking cessation referral)

Sponsor

Physician Affiliate Group of New York

Source: clinicaltrials.gov

Share:
Add to list

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Study ID: NCT05141682
Start Date: 2022-06-29
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

27

Intervention / Treatment

Oral Azacitidine

Sponsor

Jonathan Brammer

Source: clinicaltrials.gov

Share:
Add to list

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Study ID: NCT06251973
Start Date: 2024-02-01
End Date: 2027-08-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

37

Intervention / Treatment

AgenT-797

Botensilimab

The supportilimab

Ramsirumb

Paclitaxel

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Study ID: NCT05281731
Start Date: 2022-04-18
End Date: 2028-11-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Sonobiopsy

Research blood

Cancer Personalized Profiling

Definity®

Sponsor

Washington University School of Medicine

Source: clinicaltrials.gov

Share:
Add to list

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Study ID: NCT05746182
Start Date: 2023-04-07
End Date: 2025-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Hereditary Cancer Panel

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list